Avi Biopharma

Technologies Siga, based in Corvallis, OR, is a leader in global health committed to developing innovative medicines to prevent and treat emerging infectious diseases, particularly orthopoxviruses like smallpox and mpox. With a focus on advancing global health security, Siga collaborates with governments, commercial organizations, and foundations to combat the significant threats posed by infectious diseases. The company's flagship product, TPOXX (tecovirimat), is a highly targeted antiviral treatment with a strong safety profile, approved for use against orthopoxvirus infections in several regions. Siga's proactive approach and partnerships across over 30 countries enable it to respond swiftly to outbreaks and enhance public health preparedness worldwide. Generated from the website